AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31152545
Drug: Aronia whole
RxNorm normalized name: Aronia arbutifolia whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aronia whole fruit powder (12 mg, 10 g berries)
Trial: 31152545
Drug: Aronia extract
RxNorm normalized name: Aronia melanocarpa fruit extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aronia extract powder (116 mg, 75 g berries)
Trial: 26431983
Drug: ID 15
RxNorm normalized name: THYROID 15MG CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ID 15 μg HA
Trial: 26431983
Drug: ID 6
RxNorm normalized name: isoniazid 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ID 6 μg HA
Trial: 26431983
Drug: ID 9
RxNorm normalized name: Myeloid 9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ID 9 μg HA
Trial: 26431983
Drug: SC 15
RxNorm normalized name: Univasc 15mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC 15 μg HA
Trial: 26431983
Drug: ID 15
RxNorm normalized name: THYROID 15MG CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ID 15 μg HA (single or two doses)
Trial: 26431983
Drug: SC vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC vaccine
Trial: 17389293
Drug: Web-based proactive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based proactive system (PRECARES) with 2 monthly letters and follow-up calls
Trial: 11865836
Drug: Pentoxifylline (PXF;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PXF; 400 mg, 3 times daily)
Trial: 10529021
Drug: Hydromorphone (HYD)
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydromorphone (HYD) 0 mg
Trial: 10529021
Drug: Hydromorphone (HYD)
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydromorphone (HYD) 4 mg
Trial: 10529021
Drug: Hydromorphone (HYD)
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydromorphone (HYD) 8 mg
Trial: 10529021
Drug: Hydromorphone (HYD)
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydromorphone (HYD) 16 mg
Trial: 7773850
Drug: Antifungal denture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antifungal denture soaking solution (48 mL nystatin liquid, 100,000 IU/mL, dissolved in 432 mL of distilled water producing 10,000 IU nystatin/mL solution) used as an adjunct to nystatin vaginal lozenge (100,000 IU/g, dissolved in the mouth three times daily for seven days)
Trial: 7773850
Drug: Antifungal denture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antifungal denture soaking solution
Trial: 1691385
Drug: Felodipine-ER 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine-ER 5 mg once daily (n = 49)
Trial: 29986613
Drug: Intermittent oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent oxytocin infusion
Trial: 26309128
Drug: Continued oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continued oxytocin infusion
Trial: 31083052
Drug: Cognitive Behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavior Therapy (CBT) plus enhanced usual care
Trial: 16421131
Drug: Active monitoring
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active monitoring (n = 69, simple tablet count and electronic monitoring)
Trial: 16421131
Drug: Simple tablet
RxNorm normalized name: Monistat Simple Therapy
DrugBank: Octisalate (DB11062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simple tablet count
Trial: 14738230
Drug: Theophylline (2x250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (2x250 mg x day(‐1))
Trial: 14738230
Drug: Acetazolamide (2x250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (2x250 mg x day(‐1))
Trial: 8996307
Drug: Dihydrocodeine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydrocodeine (1 mg/kg body weight)
Trial: 8097802
Drug: oral captopril
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral captopril (n = 8)
Trial: 31520460
Drug: Coblopasvir (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coblopasvir (30 or 60 mg) plus Sofosbuvir (400 mg) once daily for 12 weeks
Trial: 31520460
Drug: Coblopasvir (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coblopasvir (60 mg) plus Sofosbuvir (400 mg) once daily for 12 weeks (for patients with cirrhosis)
Trial: 30563215
Drug: Daily administration
RxNorm normalized name: Prevpac 30mg-500mg-500mg Daily Administration Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily administration of vitamin D (7 drops, 1750 IU/day)
Trial: 30563215
Drug: Monthly administration
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly administration of vitamin D (50,000 IU/month)
Trial: 22439742
Drug: Trimodality therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimodality therapy including iodine-125 brachytherapy (125I-BT), external beam radiation therapy (EBRT), and 6-month combined androgen blockade (CAB) followed by 2 years of adjuvant hormone therapy (HT) with luteinizing hormone-releasing hormone agonist.
Trial: 22439742
Drug: Trimodality therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimodality therapy including iodine-125 brachytherapy (125I-BT), external beam radiation therapy (EBRT), and 6-month combined androgen blockade (CAB) without long-term hormone therapy.
Trial: 11828745
Drug: Corticosteroid creams
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid creams (Lidomex) alone
Trial: 11828745
Drug: Admixture of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Admixture of Lidomex ointment and urea/heparinoid ointments
Trial: 11828745
Drug: Ointments alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ointments alone
Trial: 6111126
Drug: Flunitrazepam (Rohypnol)
RxNorm normalized name: flunitrazepam
DrugBank: Flunitrazepam (DB01544)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam (Rohypnol) 2 mg
Trial: 18757088
Drug: Ivabradine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivabradine (5 mg, with intention to increase to 7.5 mg twice a day)
Trial: 15750103
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg once daily for a mean duration of 27 days (SD 12.2 days)
Trial: 15750103
Drug: Placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for a mean duration of 27 days (SD 13.9 days)
Trial: 12651918
Drug: Low-dose sodium
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose sodium nitroprusside (SNP) infusion during hyperthermia at Site B
Trial: 12651918
Drug: Low-dose sodium
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose sodium nitroprusside (SNP) infusion during hyperthermia at Site C
Trial: 12651918
Drug: Low-dose sodium
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose sodium nitroprusside (SNP) infusion during hyperthermia at Sites B and C
Trial: 10961763
Drug: Cocaine hydrochloride
RxNorm normalized name: Cocaine Hydrochloride
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine hydrochloride (10% solution, 1 ml, 40-50 mg per application)
Trial: 10961763
Drug: Lidocaine (10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (10% solution, 1 ml)
Trial: 31775699
Drug: Vlog doing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vlog doing a challenge with fruit and vegetables (e.g., contests, tricks, games)
Trial: 22683252
Drug: PF 1
RxNorm normalized name: APF 1.23% Dental Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF 1 mg + ranibizumab (combination) Q4W
Trial: 22683252
Drug: PF 1
RxNorm normalized name: APF 1.23% Dental Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF 1 mg every 4 weeks (Q4W)
Trial: 22683252
Drug: PF 3
RxNorm normalized name: Solbar Zinc SPF 38
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF 3 mg Q4W
Trial: 22683252
Drug: PF 3
RxNorm normalized name: Solbar Zinc SPF 38
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF 3 mg every 2 weeks (Q2W)
Trial: 22683252
Drug: PF monotherapy
RxNorm normalized name: PF-06459988
DrugBank: PF-06459988 (DB14768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF monotherapy groups
Trial: 18523642
Drug: Home based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home based intervention for caregivers, including information on dementia, guidance on behaviour management, psychiatric assessment, and psychotropic medication if needed.
Trial: 11994976
Drug: All-trans-retinoic acid
RxNorm normalized name: all-trans-Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All-trans-retinoic acid (ATRA) alone (15, 45, or 75 mg/m²/day on alternate days for 21 days)
Trial: 1816813
Drug: 2% epinephrine-free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% epinephrine-free Articain solution (Ultracain 2%)
Trial: 1816813
Drug: 4% Articain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% Articain solution with epinephrine (Ultracain D-S)
Trial: 6095602
Drug: Chemotherapy (bleomycin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (bleomycin, methotrexate, vincristine) before irradiation
Trial: 31622159
Drug: Carbohydrate gel
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate gel ingestion
Trial: 19803574
Drug: Brief motivational
RxNorm normalized name: ALCOHOL 300 mL in 375 mL TOPICAL LIQUID [Nelsons Clean Brier Tennessee Handwash]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief motivational treatment (telephone motivational interview and mailed self-help workbook)
Trial: 19803574
Drug: Brief motivational
RxNorm normalized name: ALCOHOL 300 mL in 375 mL TOPICAL LIQUID [Nelsons Clean Brier Tennessee Handwash]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief motivational booster treatment (telephone motivational interview, workbook, and 6 booster calls over 9 months)
Trial: 19803574
Drug: Brief booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief booster treatment
Trial: 9414143
Drug: Cilostazol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol (100 mg)
Trial: 9414143
Drug: Theophylline (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (200 mg)
Trial: 30770308
Drug: Lenalidomide with
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide with dose reductions
Trial: 27402596
Drug: Acute administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acute administration of ghrelin
Trial: 22432824
Drug: Intraligamentary injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraligamentary injection of piroxicam (0.4 mL)
Trial: 22432824
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (intraligamentary injection of lidocaine, 0.4 mL)
Trial: 19158153
Drug: Treatment by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment by female physicians
Trial: 19158153
Drug: Treatment by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment by male physicians
Trial: 17192771
Drug: 1,4-butanediol (BD)
DrugBank: 1,4-Butanediol (DB01955)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,4-butanediol (BD) 25 mg/kg
Trial: 15114226
Drug: Intravenous pentazocine
RxNorm normalized name: Pentazocine
DrugBank: Pentazocine (DB00652)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous pentazocine (0.5 mg/kg)
Trial: 9779697
Drug: OTFC (dose-titrated)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OTFC (dose-titrated)
Trial: 9779697
Drug: Usual breakthrough
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual breakthrough medication
Trial: 3339482
Drug: Intensive education
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive education program for internal medicine residents
Trial: 23241989
Drug: DTaP₅‐IPV‐Hib‐HepB with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP₅‐IPV‐Hib‐HepB with PCV7 administered 1 month later
Trial: 12868995
Drug: Basiliximab plus
RxNorm normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Basiliximab plus early low-dose cyclosporin
Trial: 10720881
Drug: Irbesartan (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (150 mg/day for 8 weeks)
Trial: 20182403
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection (IVT) of 4 mg triamcinolone acetonide
Trial: 20182403
Drug: Subtenon infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subtenon infusion (STI) of 40 mg triamcinolone acetonide
Trial: 16264062
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate dry powder inhaler (MF-DPI) 400 mug once daily in the evening
Trial: 16264062
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate dry powder inhaler (MF-DPI) 200 mug twice daily
Trial: 10223933
Drug: SB 209763
RxNorm normalized name: SB 224289
DrugBank: SB 224289 (DB17052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB 209763 (10 mg/kg)
Trial: 10223933
Drug: SB 209763
RxNorm normalized name: SB 224289
DrugBank: SB 224289 (DB17052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB 209763 (various doses: 0.25, 1.25, 5.0, or 10.0 mg/kg)
Trial: 10223933
Drug: SB 209763
RxNorm normalized name: SB 224289
DrugBank: SB 224289 (DB17052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB 209763 (1.25 to 10.0 mg/kg)
Trial: 25384
Drug: Antacid prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid prophylaxis (hourly titration to keep gastric pH above 3.5)
Trial: 25384
Drug: Antacid medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid medication (for those who bled in control group)
Trial: 30760846
Drug: Nasal spray
RxNorm normalized name: Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal spray (0.5 mL of 5% phenylephrine)
Trial: 24184983
Drug: Artesunate treatment
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artesunate treatment
Trial: 28289193
Drug: Artesunate treatment
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artesunate treatment in patients with kelch13 mutant parasites
Trial: 26343840
Drug: Prophylactic antibiotics
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antibiotics for 7 days plus standard stroke unit care
Trial: 19270033
Drug: Modafinil (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (100 mg daily for 7 days followed by 200 mg daily for 7 days)
Trial: 16706692
Drug: Diclofenac 75
RxNorm normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 75 mg orally, twice a day for 5 days (acute gout arthritis)
Trial: 16706692
Drug: Diclofenac 50
RxNorm normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 50 mg orally, twice a day for 21 days (chronic pyrophosphate arthropathy)
Trial: 16706692
Drug: Diclofenac 50
RxNorm normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 50 mg orally, twice a day for 21 days (chronic hydroxyapatite arthropathy)
Trial: 11103185
Drug: Propofol 6‐8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 6‐8 mg kg‐1 h‐1
Trial: 3534317
Drug: Phenoxybenzamine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenoxybenzamine (10 mg, orally twice daily for 3 days)
Trial: 3534317
Drug: Carbachol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbachol (2 mg, orally twice daily for 3 days)
Trial: 3534317
Drug: Placebo (orally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (orally twice daily for 3 days)
Trial: 3076867
Drug: Tetracycline eye
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetracycline eye ointment, twice daily for five days each month for six months
Trial: 3076867
Drug: Oral doxycycline,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doxycycline, 5 mg/kg body weight weekly for three weeks
Trial: 3076867
Drug: Oral sulphametopyrazine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sulphametopyrazine, 35 mg/kg body weight weekly for three weeks
Trial: 23237736
Drug: Low-dose vaporized
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose vaporized cannabis (1.29%)
Trial: 23237736
Drug: Medium-dose vaporized
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose vaporized cannabis (3.53%)
Trial: 9316509
Drug: Probucol (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol (1,000 mg/day)
Trial: 15059707
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no lipid-lowering therapy)
Trial: 8403306
Drug: Ketanserin (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (loading dose, 40 mg 1 hour before PTCA; maintenance dose, 40 mg bid for 6 months)
Trial: 3094627
Drug: Fluphenazine decanoate
RxNorm normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluphenazine decanoate (active drug)
Trial: 29673395
Drug: 4-month regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-month regimen using revised WHO paediatric anti-tuberculosis drug doses
Trial: 29673395
Drug: 6-month regimen
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month regimen using revised WHO paediatric anti-tuberculosis drug doses
Trial: 28606567
Drug: Wellmune 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wellmune 250 mg/d
Trial: 26520140
Drug: Delayed intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed intervention group receiving periodontal treatment 24 months after baseline.
Trial: 23735703
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy (PRE)
Trial: 23735703
Drug: Perioperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative chemotherapy (PERI)
Trial: 16567126
Drug: Metoprolol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (mean dose 154 mg)
Trial: 16567126
Drug: Metoprolol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (mean dose 158 mg)
Trial: 14565651
Drug: No cytokine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No cytokine treatment
Trial: 10425883
Drug: Klebsiella pneumoniae
RxNorm normalized name: Klebsiella pneumoniae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Klebsiella pneumoniae glycoproteins extract (1 g/day for one week a month for three months)
Trial: 2197428
Drug: Ethoglucid (0.565
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethoglucid (0.565 gm, solution of 1%) weekly for 6 weeks, then monthly for 1 year
Trial: 2197428
Drug: Keyhole‐limpet hemocyanin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Keyhole‐limpet hemocyanin (1 mg intracutaneously, then 30 mg bladder instillations weekly for 6 weeks, then monthly for 1 year)
Trial: 24699062
Drug: Single infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single infusion of ketamine (0.5 mg/kg)
Trial: 22149464
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received only physical therapy and rehabilitation (PTR) for 4 weeks
Trial: 20798227
Drug: Subjects with
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects with TSH<0.3 mIU/l
Trial: 20798227
Drug: Subjects with
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects with TSH>10 mIU/l
Trial: 17700388
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg weekly
Trial: 26185417
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg weekly